A_loading_dose/continuous_infusion_schedule_of_fludarabine_phosphate_in_chronic_lymphocytic_leukemia._Using_a_loading_dose/continuous_infusion_schedule,_fludarabine_phosphate_was_administered_to_51_patients_with_previously_treated_chronic_lymphocytic_leukemia_(CLL)._All_patients_had_evidence_of_active_disease,_and_the_majority_had_advanced_Rai_stages._Of_the_42_patients_assessable_for_response,_22_(52%)_achieved_a_partial_response,_five_(12%)_had_stable_disease,_and_15_(36%)_progressed._Thirteen_of_the_22_responders_improved_their_Rai_stages_with_fludarabine_therapy,_including_six_patients_who_achieved_stage_0._Response_rates_for_pretreatment_stages_III_and_IV_were_60%_and_53%,_respectively._Patients_with_final_Rai_stages_0_to_II_had_better_survival_than_those_with_stages_III_and_IV._Patients_who_had_undergone_splenectomy_before_starting_therapy_were_more_likely_to_respond._Myelosuppression_was_the_primary_toxicity_and_did_not_appear_to_be_cumulative._Severe_leukopenia_and_thrombocytopenia,_although_infrequent,_were_associated_with_several_deaths_in_the_early_cycles_of_treatment._Nonhematologic_toxicity_was_mild_with_no_serious_neurotoxicity_noted._Infections_were_common_with_22_minor,_18_major,_and_10_fatal_episodes._Fludarabine_phosphate_by_this_alternative_dosing_schedule_is_effective_in_refractory_advanced_CLL_and_is_well_tolerated_by_the_majority_of_patients.